Rhythm Pharmaceuticals (RYTM) and the Raymond A. Wood Foundation announced a new research collaboration to study the impact of fatigue on persons with craniopharyngioma. “We are excited to partner with the Raymond A. Wood Foundation on this survey to learn more about fatigue and its effects related to craniopharyngiomas,” said David Meeker, M.D., Chairman, Chief Executive Officer and President of Rhythm. “Learning directly from patients and caregivers is important to advancing our understanding of craniopharyngiomas and fatigue and the consequences for improving care for patients.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RYTM:
- Buy Rating Reaffirmed for Rhythm Pharmaceuticals Amid Positive Setmelanotide Trial Expectations
- Buy Rating for Rhythm Pharmaceuticals Driven by Promising Phase 3 Trial Results and Market Opportunity for Setmelanotide
- Rhythm Pharmaceuticals assumed with an Overweight at Morgan Stanley
- Promising Outlook for Rhythm Pharmaceuticals: Buy Rating Backed by Positive Phase 3 Study Expectations and Market Potential
- Promising Market Potential for Rhythm Pharmaceuticals’ Setmelanotide in Treating Hypothalamic Obesity